ArticleBiotechnology letters2025
Identification of antifungal metabolites from a soil-derived Streptomyces strain active against Fusarium graminearum using genome mining.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microbes derived from soil environments are well-recognized as prolific producers of bioactive secondary metabolites, making significant contributions to the advancement of antibiotic research. In this study, we isolated a soil-derived Streptomyces strain, designated Streptomyces sp. AHU1, which exhibited potent antifungal activity against Fusarium graminearum, the primary causative agent of Fusarium head blight. The potential of Streptomyces sp. AHU1 as a novel phytopathogenic fungicide was validated through in vitro antifungal assays and infection bioassays conducted on wheat seedlings. Whole genome sequencing combined with anti-SMASH genome mining identified approximately 34 biosynthetic gene clusters (BGCs) within the genome of Streptomyces sp. AHU1. Targeted isolation and functional analysis of these BGCs revealed that the antifungal activity is primarily attributed to lucensomycin, a previously characterized antifungal compound. This study underscores the potential of Streptomyces sp. AHU1 as a promising agent for sustainable crop protection and highlights the effectiveness of integrating bioassay-based screening with genome mining for BGC characterization as a robust strategy for the discovery of novel phytopathogenic fungicides.
Indexed as
Identifiers
40514609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.